Contact the University of Wisconsin Carbone Cancer Center


University of Wisconsin Prostate and Genitourinary Cancer Program (UWPGCP)

The goal of the University of Wisconsin Prostate and Genitourinary Cancer Program (UWPGCP) is to provide innovative and effective treatment for patients with genitourinary cancer.
UWPGCP is part of the UW Carbone Cancer Center (UWCCC), the only cancer center in Wisconsin recognized and funded by the National Cancer Institute for its research and expertise in dealing with cancer. The program utilizes a multi-modality approach to treating cancer. It also offers multiple options (surgery, radiation and chemotherapy) combined with the latest research developments to target the cancer as precisely and effectively as possible.
UWPGCP provides additional support, including nutrition and psychological help, for patients fighting cancer. Fellowship-trained, nationally recognized cancer experts are willing to provide opinions and manage complex and difficult GU cancer in a timely and efficient manner.
UWPGCP is also conducts research in chemoprevention which uses agents to reduce the risk of developing cancer or to reduce the chance that cancer will recur.
Prevention Strategies
The University of Wisconsin Prostate and Genitourinary Cancer Program conducts research in the areas of chemoprevention, early events in carcinogenesis, and biological markers of tumor recurrence and progression in bladder cancer and other genitourinary malignancies.
We are particularly interested in evaluating agents which may prolong the interval to tumor recurrence and progression. Based on laboratory data and recent clinical trials, agents which show great promise in chemoprevention include DFMO and cyclooxygenase (COX)-2 selective inhibitors. These agents are being evaluated in patients at high risk for tumor recurrence and progression, such as those with carcinoma in situ or high grade superficial bladder cancer. The ability to more accurately predict which patients with superficial bladder cancer will progress will also allow the staff at UWCCC to treat these patients more effectively. This research will hopefully enhance bladder-sparing approaches for treating bladder cancer, in which fewer patients with superficial bladder cancer will ultimately require radical cystectomy.
UWPGCP has the resources to build a program in chemoprevention research, and as a tertiary referral center, many patients with genitourinary cancers such as bladder cancer, may benefit from this research. It is our hope that these research efforts will lead to the prevention and early detection of bladder cancer, more accurate staging, appropriate patient selection for treatment, and more effective therapies.
Clinical cancer prevention trials in bladder and prostate cancer are also conducted to evaluate the effects of putative chemoprevention agents. One of these trials is designed to evaluate the effects of a vitamin D analogue on intermediate biomarker expression in prostate cancer. Furthermore, a bladder cancer chemoprevention trial evaluating difluoromethylornithine (DFMO) in the prevention of superficial bladder cancer has recently been completed.
We are currently developing cancer chemoprevention trials to understand dietary supplements work in reducing or preventing the development of genitourinary cancers.